Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Illumina (ILMN) stock in plain English

Free brief · no signupStart here
ILMNPublished Nov 9, 2026
Illumina Inc
Healthcare · Diagnostics & Research
Manufactures and sells gene-sequencing machines and specialized chemical consumables to research laboratories globally. Provides software and testing services to analyze genomic data.
Assets:
23,000+ Active SystemsInstalled sequencer base driving recurring consumables revenue
San Diego FacilitiesCentral corporate campus and primary sequencing instrument manufacturing
9,200 Global EmployeesWorldwide workforce across research, sales, and manufacturing operations
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
-4.45%$200.65
$30.34B
34.5×
$4.54B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 09, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ILMN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Illumina (ILMN) do?

Illumina Inc (ILMN) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Manufactures and sells gene-sequencing machines and specialized chemical consumables to research laboratories globally. Provides software and testing services to analyze genomic data. Generates recurring high-margin revenue by selling proprietary chemicals required to operate its installed DNA. It is worth $30.34B on the market and sold $4.54B over the last year.

Market cap
$30.34B
P/E ratio
34.5×
Annual sales
$4.54B
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 09, 2026

Brands and businesses behind ILMN

  • NovaSeq: Sells high-throughput genomic sequencers and consumables to large-scale laboratories and genomics centers.
  • NextSeq: Provides mid-throughput benchtop sequencing systems and chemical kits to clinical and academic researchers.
  • MiSeq: Produces low-throughput targeted sequencing instruments and reagent cartridges for smaller clinical laboratories.

ILMN’s flags, in plain English

Each flag is a number from Illumina’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 09, 2026.

Stupid Cash

Can pay this year's bills 2.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 68.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earns Its Keep

Earns 32.4% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Priced for Perfection

Priced at 34.5 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about ILMN

How big is Illumina?

Illumina’s market cap is $30.34B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $4.54B: what customers paid the company over the last year, before any costs.

What is ILMN’s P/E ratio?

ILMN’s P/E ratio is 34.5×. Investors pay about 34.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ILMN?

Emerging competitors offer lower-cost short-read sequencing alternatives that challenge current pricing power. That is one risk on Illumina’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Illumina’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ILMN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card